Patents by Inventor Phillip Müller
Phillip Müller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12325275Abstract: A damping arrangement for an axle of an active chassis of a motor vehicle. A damping system interacts with each wheel of the axle, each damping system has the following: a damper having a double-acting hydraulic cylinder and a piston, a hydraulic pump and an electric motor for driving the hydraulic pump, a hydraulic unit having a hydraulic reservoir and valves. The hydraulic pump and the hydraulic unit of the respective damping system interact with the respective hydraulic cylinder in such a manner that, depending on the conveyance direction of the hydraulic pump, a movement of the piston can be provided in a first or in a second actuation direction. The electric motors of both damping systems are arranged with axially aligned rotational axes in a casing and can be regulated by a common control device which has electronic construction groups which are arranged on at least one circuit board.Type: GrantFiled: March 22, 2024Date of Patent: June 10, 2025Assignees: Dr. Ing. h.c. F. Porsche Aktiengesellschaft, RAPA Automotive GmbH & Co. KGInventors: Tim Rubitzko, Phillip Müller
-
Patent number: 12179542Abstract: Damping arrangement for an axle of an active chassis of a motor vehicle. A damping system interacts with each wheel of the axle. Each of the damping systems includes the following assemblies: a damper including a double-acting hydraulic cylinder and a piston, a hydraulic pump and an electric motor for driving same, and a hydraulic unit which includes a hydraulic reservoir and valves. The hydraulic pump and the hydraulic unit of the respective damping system interact with hydraulic chambers of the hydraulic cylinder in such a manner that a movement of the piston in a first or in a second operating direction can be provided depending on the delivery direction of the hydraulic pump. The electric motors of both damping systems are connected to a common control device and can be actuated thereby, wherein the common control device has electronic assemblies which are distributed on different printed circuit boards.Type: GrantFiled: April 1, 2024Date of Patent: December 31, 2024Assignees: Dr. Ing. h.c. F. Porsche Aktiengesellschaft, Silver Atena GmbHInventors: Phillip Müller, Martin Klepatsch
-
Publication number: 20240336102Abstract: A damping arrangement for an axle of an active chassis of a motor vehicle. A damping system interacts with each wheel of the axle, each damping system has the following: a damper having a double-acting hydraulic cylinder and a piston, a hydraulic pump and an electric motor for driving the hydraulic pump, a hydraulic unit having a hydraulic reservoir and valves. The hydraulic pump and the hydraulic unit of the respective damping system interact with the respective hydraulic cylinder in such a manner that, depending on the conveyance direction of the hydraulic pump, a movement of the piston can be provided in a first or in a second actuation direction. The electric motors of both damping systems are arranged with axially aligned rotational axes in a casing and can be regulated by a common control device which has electronic construction groups which are arranged on at least one circuit board.Type: ApplicationFiled: March 22, 2024Publication date: October 10, 2024Applicants: Dr. Ing. h.c. F. Porsche Aktiengesellschaft, RAPA Automotive GmbH & Co. KGInventors: Tim RUBITZKO, Phillip MÜLLER
-
Publication number: 20240336143Abstract: A high-voltage component of an electric vehicle, which high-voltage component can be connected to a high-voltage traction battery of the electric vehicle. The high-voltage component includes at least one electric machine; a power electronic assembly which is configured to convert the high voltage of the traction battery into an operating voltage for the electric machine; and a control assembly which can be connected to a low-voltage on-board electrical system of the electric vehicle. The control assembly includes a control unit which is configured to control the operation of the high-voltage component. The power electronic assembly has an integrated DC-DC voltage converter which is connected to the control assembly and which is designed to convert the high voltage of the traction battery into a voltage corresponding to the voltage of the low-voltage on-board electrical system of the electric vehicle.Type: ApplicationFiled: April 1, 2024Publication date: October 10, 2024Applicant: Dr. Ing. h.c.F. Porsche AktiengesellschaftInventor: Phillip Müller
-
Publication number: 20240336105Abstract: Damping arrangement for an axle of an active chassis of a motor vehicle. A damping system interacts with each wheel of the axle. Each of the damping systems includes the following assemblies: a damper including a double-acting hydraulic cylinder and a piston, a hydraulic pump and an electric motor for driving same, and a hydraulic unit which includes a hydraulic reservoir and valves. The hydraulic pump and the hydraulic unit of the respective damping system interact with hydraulic chambers of the hydraulic cylinder in such a manner that a movement of the piston in a first or in a second operating direction can be provided depending on the delivery direction of the hydraulic pump. The electric motors of both damping systems are connected to a common control device and can be actuated thereby, wherein the common control device has electronic assemblies which are distributed on different printed circuit boards.Type: ApplicationFiled: April 1, 2024Publication date: October 10, 2024Applicant: Dr. Ing. h.c. F. Porsche AktiengesellschaftInventor: Phillip Müller
-
Patent number: 10383930Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.Type: GrantFiled: August 10, 2018Date of Patent: August 20, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Müller, Julia Leibold, Valentina Goldfinger
-
Patent number: 10238727Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.Type: GrantFiled: October 5, 2018Date of Patent: March 26, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Müller, Julia Leibold, Valentina Goldfinger
-
Publication number: 20190054160Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.Type: ApplicationFiled: October 5, 2018Publication date: February 21, 2019Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Phillip MÜLLER, Julia LEIBOLD, Valentina GOLDFINGER
-
Publication number: 20190000947Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: September 18, 2018Publication date: January 3, 2019Inventors: Toni WEINSCHENK, Andrea MAHR, Jens FRITSCHE, Phillip MÜLLER, Anita WIEBE, Sara KUTSCHER
-
Publication number: 20180344827Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.Type: ApplicationFiled: August 10, 2018Publication date: December 6, 2018Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Phillip MÜLLER, Julia LEIBOLD, Valentina GOLDFINGER
-
Patent number: 7317398Abstract: An object is provided with a label for identifying in a cable-less manner by an electromagnetic radiation. The inventive label comprises at least one antenna receiving an incident electromagnetic signal and characterized reducing the influence of dispersion or straying capacities caused by the object on file remnant properties of the label. Such that the label can be applied to any object, particularly optical or magneto-optical data carriers.Type: GrantFiled: April 26, 2002Date of Patent: January 8, 2008Assignee: Bibliotheca RFID Library Systems AGInventor: Phillip Müller